Vol. 7 (09) pp. 247-253 DOI: 10.21474/IJAR01/9654

IS HEPATITIS C LIKE A HOT KNIFE THROUGH BUTTER (A SILENT KILLER).

, , , , , and
  • Apollo Institute of Medical Science and Research Institute, Jubilee Hills, Hyderabad, India.
  • Avalon University School of Medicine, Curacao, Central America.
  • Acharya NagarjunaUniversity,NagarjunaNagar,Guntur, Andhra Pradesh,,India.
8 Downloads 74 Views
Crossref

Download Full Paper (PDF)

Abstract

Hepatitis C virus belongs to the flavi virus family. Hepatitis C virus is known as Non-A and Non-B hepatitis. It exists in six genotypes with different worldwide distribution. It is a curable disease.HCV is the common cause of transfusion and liver transplant-associated hepatitis. It can also be considered as STD and can be transmitted at birth from an HCV infected mother. Acute disease is usually mild but 70% of those infected develop chronic disease. A high percentage of individuals had an asymptomatic disease that leads to cirrhosis and liver failure. Hence each year, the percutaneous injury resulted in around 16,000 HCV and caused about 8000 deaths in the USA. Clinically acute infection with HCV is milder than infection with HBV (1).

Keywords

Article Analytics

References

  1. WarrenLevinson,Review of Medical Microbiology,13 thEd,McGraw Hill Edu,PP 338
  2. Bennet S,Genson RN,MC Allister GE,Hutchenson et al.Detection of HCV RNA,indirect blood spot,J.Cli.Virol,2012,15;2012;54,106-9
  3. Bosch FX, Ribes J, Diaz M, Cleries R Primary liver cancer; Worldwide incidence and trends Gastroenterology.2004;127 (5.suppl1)55-16
  4. WHO global policy report on the preventive and control of viral hepatitis 2013,accessed on August 2014Mayo.M.Extrahepatic manifestations of hepatitis-C- infection.Am.JMed.Sci. 2002;325;135-48
  5. WHO guidelines on hepatitis B and C testing World health org,2017
  6. Vogel M, Deterding K?Wiegand?et.al,?initial presentation of acute hepatitis?C? virus(HCV)infection among HIV negative and HIV positive individual experience from 2 largeGerman?networks on the study of acute?HIV infection.Clin.Infect.Dis 2009,49(2);317-9,author reply 319.
  7. BenhamouY,Di Martino V,Bochet.M,al, Factors affecting liver fibrosis, in human immunodeficiency virus?and hepatitis C virus-coinfected?patients.Impact of protease inhibitor therapy.Hepatology.2001;54(2),283-7.
  8. Qureshi?N, Kreuzberg C, Luchters?G,?alEffect?of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus?coinfection.Lancet.2003;362 (9397);1708-13
  9. KuoG,ChooQL,Alter?et.al.Anassay?for circulating antibodies to?major etiologic virus of human non?A non B hepatitisScience 1889;244;362-4
  10. Wandler G,G S PonerT,Bregezer et al.Swiss HIV cohort study.A rapid evolving epidemic cli. Inf.Dis.,2012;55;1408-16
  11. GhislaV,ScherrerAU,Nicca D, BrunDL,FehrJS,IncidenceofHCV positive and Negative men who have sex with men 2000-2016.A systemic review and meta analysis infection,2017;45:309-21
  12. J, Hoffnagle JH .Mechanism of action of interferon and ribavirin in the treatment of hepatitis C Nature 2005;436;967-72.
  13. Van Santen Dk,Dervan Helm et al.Lack of discipline in HCV incidence among HIV positive men who have sex with men during 1990-2014.J.Hepatol.2017;67:255-62
  14. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46 [PMID: 12407575 DOI: 10.1002/ hep.1840360706] 4 Pawlotsky JM. T
  15. LoReV,KallanMJ,TateJP,etal.Hepaticdecompensation.Inanti viral treated patients Co-infected with HIV and HCV compared with HCV monitored patients,A cohort study.Ann.Intr.Med.2014;160:369-79.Bigger CB, Brasky KM,?Laford RE.
  16. DNA microarray analysis of chimpanzees?liver during acute resolving hepatitis C virus?infection.J.Virology.2001;75(15) 7059-66
  17. Al, Pezacki JP, Wodicka L?et.al,?Genomic analysis of the host response to hepatitis?C? virus infection.Proc.Natl.AcadSci USA,2002;99(24);15669-74
  18. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, GoncalesJr.Fl,et.alCombination of peginterferon alfa-2a(40kd) plus ribavirin?in patients with chronic hepatitis C virus?infection.N.Engl.J.Med.2002;347;975-82
  19. Mann MP, Mc Hutchinson G,GordonSC,Rustgi VK, Shiffman ML, ReindollarR,al, Peginterferon-alfa2b?plus ribavirin compared with interferon alfa?2b plus ribavirin for initial treatment of chronic hepatitis C?;a randomized trial.Lancet.2001;358;958-65.
  20. Eine icterus epidemic.BerlinKlin Wochenschr.1885;22;2
  21. S, FilesJP.Hammond J.
  22. infectious hepatitis;?evidence for two distinctive clinical, epidemiological, and immunological?types of infection.JAMA 1967;200;365-73
  23. Boyer, JL (2001).?Liver cirrhosis and its development: proceedings of the Falk Symposium 115. Springer. pp.?344. ISBN?978-0-7923-8760-2
  24. Bradly DW,McCauslandKA,CookEH,et.al.Post-transfusion?non-A, Non-B hepatitis in?chimpanzees;?physicochemical evidence that the?tubule-forming?agent is a small, enveloped?virus.Gastroenterology,1985;88;773-9.
  25. Choo QL,KuoG,WeinerAJ,et.al.Isolation?of a CDNA clone derived from a blood-borne?Non-A,non-B viral hepatitis genome.Science. 1989;244;;359-62
  26. Ferraric,New perspectives for T cell based HCV vaccines J.Hepatol.2006,45;163-165
  27. FolgoriA,Caponi S, Ruggeri L,etal.A T-Cell HCV vaccine eliciting effective immunity agaist heterologous virus challenge in Chimpanzees.Nat.Med.2006;12;190-197
  28. "Hepatitis C".?The Lancet.?385?(9973): 1124?1135. doi:10.1016/S0140-6736(14)62401-6. ISSN?0140-6736. PMC?4878852. PMID?25687730
  29. Peter R.McNally,GI/Liver secretes Plus,4 th Edition,2010
  30. GeoffereyDusheiho,Hepatic C ,chapter 20,Sherlock's disease of liver and biliary system.Edited by James S,Dooly,Anna SF et al.,2011 Blackwell Publishing Ltd,
  31. Sherlock S,Hepatitis C Virus;A historical prospectiveePUBMED-NCBI.Dig.Dis.Sci.1996,Dec;41 (12 Suppl);3S-5S ;HJ,32
  32. Mahajan R,LieSj,KlevensRM,HolmbergSD,Indications for testing among reported cases of HCV infection from enhanced hepatitis.Surveillence sites in the USA 2004-2010.Am.J.Public Health 2013;103:1445-9
  33. Mc LanchlanJ.Properties of the hepatitis C virus core protein.A structural protein modulates cellular processes.J.Virol.Properties of the hepatitis C virus core proteins.A structural protein modulates cellular processes.J.Virol.Hept.;2007(1);2-14.
  34. LohmannV,KornerF,Koch JO, et al.Replication of sub genomic hepatitis C virus RNAs in hepatocelllines.Science 1999;285(5224);110-113
  35. WakitaT,PietschmannT,Keto T et al.Production of infectious hepatitis C? virus in tissue culture from a cloned viral genome.Nat.NMed. 2005 11(7);791-796
  36. Massachutts,Dept of public health.The Opioid Epidemic.Available at htpp//www.mass.gov/chapter 55.Accessed 2017
  37. Rachel Nall, RN MSN, Is there a vaccine for hepatitis C???Wed 31 October 2018, Newsletter Medical News Today
  38. PC Das and PK Das,Textbook of Medicine,Current books international 60,Lenin Saranee,Kolkatta,5 Th Edition.
  39. Ekta Gupta,?MeenuBajpai,?and?AashishChoudhary, Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays,Asian J Transfus Sci. 2014 Jan-Jun; 8(1): 19?25.
  40. Ekta Gupta,?MeenuBajpai,?and?AashishChoudhary,?Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays,Asian J Transfus Sci. 2014 Jan-Jun; 8(1): 19?25.
  41. Dow BC, Buchanan I, Munro H, Follet EA, Davidson F, Presscot LE, et al. Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood blood donors.?J Med Virol.?1996;49:132?6)
  42. Moyer VA.US preventive services task force screening for hepatitis C virus infection in adults.US preventive services task force recommendation statement.Ann.Intern.Med ,2013;159:349-57
  43. McHutchison JG, Manus MP, Muir AJ, et al.Telaprivir for previously treated chronic HCV infection.New Eng.J.Medicine,;2010;362(14);1292-303
  44. Kwo PY, Lewis EJ, McCone J et al.Efficacy?of Boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with?genotype-1 hepatitis C interferon(SPRINT-1); An open-label, randomized,4multicenter phase-2 trial.Lancet;2010;376(9742);705-16.
  45. SeneD,LimalN,Cacoub P,HCV associated extra hepatic manifestations a review.Metab Brain.Dis.2004;19,357-381
  46. CacoupP,PoynardT,GillaniP,et al. Extrahepatic manifestations of chronic hepatitis C MULTIVIRIC Group-Multidepartment Virus C ,Artritis.Rhem 1999;42;2204-12
  47. Xiaowan Yin,1,2,3,??Tingting Liu,1,4,??Zhuo Wang,1,5,??Meichen Ma,?Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals,?Front Immunol. 2018; 9: 2341.
  48. Richard L.Kradin,Diagnostic pathology of infectious disease,2010,Saunders,Elsevier publications.
 

How to Cite This Article

Raghavendra Rao M.V., Sateesh Arja, S P Pallavi, Kumar Ponnusamy, Mahendra Kumar Verma, Reshma Fatteh Jattavathu.Madhavi and Sirisha Bala. (2019); IS HEPATITIS C LIKE A HOT KNIFE THROUGH BUTTER (A SILENT KILLER)., Int. J. of Adv. Res., 7 (09), 247-253, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/9654

Corresponding Author

Prof.Morusupalli Venkata Raghavendra Rao
Apollo institute of Medical Sciences and Research,Hyderabad,India
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.